WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Why This Novo Rival Just Pulled A Bearish Move — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 4 fonti

Why This Novo Rival Just Pulled A Bearish Move

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.

Raccontata da

biopharmadive.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo1 mese fa

Why This Novo Rival Just Pulled A Bearish Move

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.

benzinga.com1 mese fa

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.

Leggi questa versione → originale

Timeline cronologica

martedì 21 luglio 2026·biopharmadive.com
Agios scraps sickle cell drug
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
martedì 21 luglio 2026·investors.com
Why This Novo Rival Just Pulled A Bearish Move
Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.

biopharmadive.com1 mese fa

Agios scraps sickle cell drug

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

Leggi questa versione → originale

endpoints.news1 mese fa

Agios’ second shot at sickle cell disease falls short

Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting approval for mitapivat in the same condition.

Leggi questa versione → originale

martedì 21 luglio 2026·

endpoints.news

Agios’ second shot at sickle cell disease falls short

Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting approval for mitapivat in the same condition.

martedì 21 luglio 2026·

benzinga.com

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.